NervGen Pharma Corp V.NGEN

Alternate Symbol(s): NGENF

Healthcare Biotechnology

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.

TSXV:NGEN - Post by User

NervGen Pharma Corp > Brian Bayley sold 100,000 shares at $ 3/share

<< Previous

Bullboard Posts

Next >>

Comment by deepoil0808on Mar 19, 2024 3:19pm

238 Views

Post# 35941338

RE:RE:RE:RE:Brian Bayley sold 100,000 shares at $ 3/share

I agree.

Fact that observers can see the trial`s success makes it very easy to know if it works or not.

Perhaps that one person who showed a little improvement was due to placebo effect, sometimes will power is very strong.

Good Luck,

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features